chrisvoncsefalvay/vaers-outcomes huggingface dataset:
I received the vaccine on Wednesday, April 7th.  I was told I had an anaphylactic reaction at the time of injection: I started sweating upon receiving the vaccine, my blood pressure dropped, and I almost passed out. I was monitored for 30 mins before being sent home. Other than some fatigue, I was fine the rest of the day.  On Thursday, April 8th, I was tired but felt fine otherwise.  Friday and Saturday, April 9th and 10th, I felt like I was back to normal and even did some light exercise.  On Sunday morning, April 10th, the left side of my body (side of injection) went numb, I had extreme vertigo, shortness of breath, and blotches that appeared in random places. It didn't look like hives, but rather looked like strips of red. I didn't feel like I was having an allergic reaction, but something did not feel right. I consider myself a pretty healthy guy with a healthy lifestyle. I did not feel the need to go to the ER quite yet, but I did have a friend come over to monitor me.  My friend did some acupuncture which helped resolve the numbness and dizziness and some of the blotches, and also mentioned concerns regarding blood circulation and potential clotting issues she thought I was having.
After 9 days of receiving de vaccine, my right arm start to itch and present redness, and the area is hot.  I visit the doctor yesterday (04/07/21) and start a treatment with the following medicines: CEFADROXIL 500 mg and CP-DEXAMETHASONE/M-DRYL.
VIOLENT BOUTS OF VOMITING AND DIARRHEA. NOT ABLE TO EAT OR DRINK ANYTHING (SOLID OR LIQUID) FOR 72 HRS AFTER SHOT.  SEVERE STOMACH CRAMPING AND EXCESSIVE BLOATING AFTER EATING OR DRINKING ANYTHING.
she had rashes; This is a spontaneous report from contactable consumer. This female consumer (patient) reported that she received the first dose of BNT162B2 at single dose for COVID-19 immunization on 03Apr2021. Relevant history and concomitant drugs were unknown. The patient reported that she was just wondering if this was from the vaccine because after 4 days after her vaccine she got rash. Outcome of event was unknown.  The patient wondered if could still take the second dose.  No follow-up attempts are needed. Information about on Lot/batch number cannot be obtained.
Information has been received from a consumer concerning her 22 month old son with no pertinent medical history, drug reactions/allergies or concomitant medication usage, who in March 2007 (exact date not reported), was vaccinated (route and site not reported) with COMVAX vaccine (lot # not reported). The patient was concomitantly vaccinated with VAQTA. In March 2007, post vaccination, the patient developed a rash. The patient did receive unspecified medical attention. No diagnostic test were performed. The patient recovered in a few days after the vaccination. No additional information is expected.
Administered the vaccine after 20hrs of first vial puncture to 2 patients; This spontaneous case was reported by a pharmacist and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (Administered the vaccine after 20hrs of first vial puncture to 2 patients) in a 24-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 002c21 and 002c21) for COVID-19 vaccination.     Concomitant products included LISINOPRIL for Blood pressure, ATORVASTATIN for Cholesterol, INSULIN GLARGINE (TOUJEO) and GLIPIZIDE (GLIPIZIDE ER) for Diabetes.   On 20-Apr-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 18-May-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On 18-May-2021, the patient experienced EXPIRED PRODUCT ADMINISTERED (Administered the vaccine after 20hrs of first vial puncture to 2 patients). At the time of the report, EXPIRED PRODUCT ADMINISTERED (Administered the vaccine after 20hrs of first vial puncture to 2 patients) had resolved.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   No treatment information was reported.   Most recent FOLLOW-UP information incorporated above includes: On 30-Jun-2021: Follow-up information received on 30-jun-2021 contains significant information of patient details, dosage details and event details.
This spontaneous report as received from a physician refers to a 10 years old female patient with no pertinent medical history and on known drug reactions or allergies.. On 01-JUN-2012, the patient was vaccinated with first intramuscular 0.5 ml GARDASIL lot # 672652/0022AE exp date 28-SEP-2014. On 03-AUG-2012, the patient was vaccinated with second intramuscular 0.5 ml GARDASIL lot # 672652AE exp date 28-SEP-2014. The physician stated, that on 02-JUN-2012 approximately, within 24 hours of received dose 1 GARDASIL experienced itching and rash at the injection site and also on her legs and on 04-AUG-2012 approximately, within 24 hours of received dose 2 GARDASIL experienced itching and rash at the injection site and also on her legs. The patient sought medical attention by calling the physician. No treatment for the events was given. Laboratory and diagnostics were not performed. The patient recovered from theses symptoms after both doses. The outcome of both rash at the injection, both itching on her legs, both rash on her legs and both itching at the injection site was reported as recovered. Additional information has been requested.
Started with a headache and neck and back pain.  Woke up the next day with numbness to my hands and feet and around my mouth.  Progressed over a week to extreme weakness and numbness and pain from the waistline down and arm weakness.  Has continued for over 5 weeks without improvement.  Have had a spinal tap, lab work several times and an MRI of head and spine.  2 ER visits, 24 hour hospital stay and multiple visits to family MD and neurologist.  Diagnosis is still unclear but possible transverse myelitis vs. Guillain Barre.  To start physical therapy next week due to weakness to lower extremities and difficulty walking.  Also developed hypertension and severe constipation.
01/03/22 presents to EC ED for "evaluation of a fall". PMHx of " atrial fibrillation, coronary artery disease, hypertension, diabetes and anemia"
about 1hr to 1 1/2hr p/vax given pt devel swollen lips & redness of eyelids & neck;
Patient had fever, nausea, redness, bruising sensitive to touch, extreme pain at the injection site, pain on arm, swelling at inj site, about 2 inch area was red and 1 inch was bruised. Patient went to urgent care to get pain med and was prescribed ibuprofen 600 mg TID.
a. Injection site tenderness which has improved in less than 24 hrs. b. chills, unquantified fever onset approximately 12 hrs after vaccine administration which improved with acetaminophen 1000mg once. Following morning, chills reappeared and improved with acetaminophen 1000mg once.
WIthin a few hours of receiving vaccine, patient developed pain, swelling, hypersensitivity, redness and mottling of several toes bilateral feet and painful subcutaneous nodules on toes
COVID-19 symptoms started either 11/16/22 or 11/17/22. It started as a mild cold with runny nose, scratchy throat, and then plugged sinuses and eventually I got wheezing in my chest as well as body aches. That's about it and I did go to an urgent care and saw an NP and she gave me an inhaler and a medication for the congestion. She told me it was an moderate case. Symptoms lasted 3 weeks, maybe even longer. I still sometimes get phlegm in my throat, but I don't know if that's due to this. I did test positive back when I first started feeling bad and took 3 home tests. I feel fine now.
My minor Tinnitus became much worse after vaccination but the condition is still getting worse over time.
Pt states that itching & redness began at site (L) arm 3 days after receiving vaccine
Began experiencing severe psychotic behavior on 3/8/2021.  These symptoms worsened on 4/15 (second dose on 4/5).  Patient became delusional and began having regular hallucinations.  She was seen in 3 different emergency rooms without any improvement in her symptoms.  She was then sent to Behavioral clinic and treated with psychotic medication.   He r symptoms began to resolve around the date of 5/8/21.  She continues to be on psychotic medication but current doctor is talking about removing these as she has seemed to stabilize.
No problem the day of getting the vaccine.  When I woke up the next morning my whole body was very achy and tired.  After lunch still tired and achy, temp was 100.3 and took a 3 hour nap.  After nap did a few household chores, fell asleep in lounge chair for about 30 minutes, ate a little dinner and went to bed at 9:30 p.m.  Did  take one Aleve at bedtime.  Didn't take any meds during the day because I read it can affect the vaccine.  Woke up Sunday (about 8:15 a.m.) feeling normal and temp 97.6.
Patient received vaccine at 9:30am on 09/02/2021. Patient called the pharmacy at 4pm on 09/02/2021 stating she is experiencing side effects including facial and tongue numbness that is radiating from her left side (side where injection received) to her right side. Patient states she is also feeling pain in her face and jaw as well as pressure in her head. Patient denied having any side effects after her first dose of vaccine. Patient was instructed to seek medical help to ensure she is not having an allergic reaction based on the tingling/numbness in her tongue. Patient agreed to seek medical attention at urgent care.  On 09/03/2021,  patient stated she went to urgent care the previous day and was referred to the ER. At the ER, they gave her a referral to a neurologist.
Post menopausal bleeding . I've not had a period in 5 years. Now I'm bleeding again.
was dizzy right away after first dose injection, followed by headache. later in the evening/next day anxiety was very high.  after second dose injection had similar issues with left arm pain dizziness. Once I received my influenza vaccine in October I was extremely dizzy, chest pain, light headed, hot flashes, spins, became dehydrated. muscle pains,  seen several specialist. still trying to figure out the issues.  missed 11 weeks of work due to the symptoms. was unable to drive missed my child's school evens/sports.
This spontaneous report was received from a registered nurse and refers to a multiple unspecified patients of unknown age and gender. The patients' concurrent conditions, medical history and concomitant medications were not reported. On an unknown dates, the patients were vaccinated with an unspecified doses of PNEUMOVAX 23 (doses, lot numbers, expiration dates, routes of administration were not reported), that had undergone multiple unspecified temperature excursions. The information regarding temperature, time frame and previous temperature excursions were unknown. The digital data logger was involved. There were no adverse effects reported. The product quality complaint was not involved. Additional information has been requested. Sender's Comments: US-009507513-1705USA004383: US-009507513-1705USA004379: US-009507513-1705USA004380: US-009507513-1705USA004381: US-009507513-1705USA004382: US-009507513-1704USA008135: US-009507513-1705USA004376: US-009507513-1705USA004378.
Injection site redness and swelling, pain, itching. Increased wheezing. Pt took BENADRYL, cool compress and used VENTOLIN inhaler = managed S/S.
Tested positive for Covid; Sick; This is a spontaneous report from a contactable consumer (patient sister). A female patient of an unspecified age received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, Lot number: UNKNOWN) via an unspecified route of administration on 01Apr2021 as single dose for COVID-19 immunization. The patients medical history and concomitant medication was not reported. It was reported that the patient had her 1st dose of Covid 19 vaccine on 01Apr2021 then on 07Apr21 the patient was really sick and then on 10Apr2021 she was tested positive for Covid and her 2nd dose was today 23Apr2021 and cannot make it. The outcome of the events was unknown.  No follow-up attempts are needed. Information about lot/batch number cannot be obtained.
Patient presented to the ED on 4/12/21. Patient presented to the ED on 4/15/21 and was subsequently admitted. These visits were within 6 weeks of receiving COVID vaccination.
09/20/13: Client reports rash appeared on legs at 9:00 PM and progressed to arms and trunk of body. Rash was itchy and red and progressively worsened by Saturday 9/21/13 AM.
Pt recvd measles vax & w/in 10 min became diaphoretic, disoriented, & fainted;
This case was reported by a physician via a sales representative and described the occurrence of swelling in a subject of unspecified age and gender who was vaccinated with INFANRIX (GlaxoSmithKline). On an unspecified date the subject received unspecified dose of INFANRIX (unknown). At an unspecified time after vaccinated with INFANRIX, the subject experienced severe swelling. At the time of reporting the outcome of the event was unspecified. The physician considered the event was probably related to vaccination with INFANRIX. This event occurred in four different subjects. The reporter indicated that they narrowed the events down to the same lot number for all cases. The lot number was not provided at the time of reporting. This case, A0722975A, serves as the master case. The other case numbers are A0722979A, A0722980A and A0722981A. Follow-up information was received on 25 April 2008, via physician, who reported the 2-month old female subject received 1st dose INFANRIX and COMVAX on 02 April 2008. On 3 April 2008, 1 day after vaccination with INFANRIX, the subject experienced swelling of the entire thigh. At the time of reporting the event was improved. The physician considered the event was related to vaccination with INFANRIX. Follow-up information was received on 25 April 2008, via sales representative who reported an additional event of fever. It was stated the physician saw in increased incidence of excessive swelling with INFANRIX. At the time of this report, the physician considered the fever probably related to vaccination with INFANRIX. Follow-up information was received on 01 May 2008, via physician, who reported the 2-month-old subject experienced limb swelling. The physician believed there was a problem with this particular lot of INFANRIX.
one patient was inadvertently administered one dose of improperly stored Varivax; no adverse effects; This spontaneous report was received from a Medical Assistant and refers to a currently 4-year-old patient of unknown gender. No information regarding the patient's pertinent medical history, drug reactions or allergies and concomitant therapies was provided. On an unknown date, the patient was vaccinated with improperly stored varicella virus vaccine live (oka/merck) (VARIVAX) injection, one dose, lot # R030606 and expiration date 23-OCT-2020 (exact dose and route of administration were not reported) for prophylaxis. The temperature was in the range of -14°C to -10°C (-12.6C) for 30 minutes. There was no previous temperature excursion reported. Digital data logger was involved. No adverse effects were reported. The outcome of product storage error was unknown. No causality assessment was provided by the reporter.
PATIENT RECEIVED AREXVY AND FLUZONE HD VACCINATIONS ON 09/18/2023. ON 09/19/2023 WHILE AT HOME SHE FELT DIZZY AND FELL DOWN BRUISING HER FACE AND GOT A SWOLLEN LIP. PATIENT REPORTED TO THE PHARMACY ON 09/23/2023
dark red rash, itchy; urticaria; dark red rash, itchy; dark red rash, itchy; A spontaneous report was received from a healthcare facility staff member concerning a patient (age and gender unknown) who received Moderna's COVID-19 Vaccine (mRNA-1273) and developed urticaria, itching at the injection site/injection site pruritus, and dark red rash at the injection site/injection site rash/injection site erythema.  The patient's medical history was not provided.  No relevant concomitant medications were reported.   On an unknown date, approximately one week prior to the onset of the events, the patient received their first of two planned doses of mRNA-1273 (batch number not provided) intramuscularly for prophylaxis of COVID-19 infection.   The patient experienced urticaria and developed an itchy, dark red rash at the injection site approximately one week after receiving vaccine.  No treatment information was provided.  Action taken with mRNA-1273 in response to the events was not provided.   The outcome of the events urticaria, itching at the injection site, and dark red rash at the injection site were not reported.  Reporter causality for the events was not provided.; Sender's Comments:  MOD-2021-011289:same reporter, different patient
NURSE ADMINISTERING VACCINE ADMINISTERED SOME DOSES AS 0.5ML INSTEAD OF 0.25ML FOR BOOSTER. WHEN ERROR WAS REALIZED SHE WAS UNSURE WHICH PATIENT RECEIVED THE 0.5ML VS 0.25ML. THIS PATIENT MAY HAVE RECEIVED 0.5ML INSTEAD OF 0.25ML.
Patient reported chills, fatigue, HA, and severe muscle pain and spasms 12 hours after given her second vaccine.  she received the BioNTech Pfizer Covid 19 vaccine
Patient given MMRV at age 15 years. Cut off age for MMRV is 12 years.
The first symptom, on the 27th in a.m., I had chest pressure or pain for about 90 minutes. I couldn't take a deep breath and I couldn't exert myself at all without it hurting in my chest.  The 2nd symptom, I went to doctor (21 days after) and he checked my platelets. I woke up three times during the night with pain in my left calf. A couple of nights previously I woke up with those same pains in my left calf, as well. It was worse pain the second time. I went to the dr and he did bloodwork. I did not have any other pains after that.
Side effects after second dose; This spontaneous case was reported by a consumer and describes the occurrence of VACCINATION COMPLICATION (Side effects after second dose) in a patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.   On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On an unknown date, the patient experienced VACCINATION COMPLICATION (Side effects after second dose). At the time of the report, VACCINATION COMPLICATION (Side effects after second dose) outcome was unknown.            The patient received both scheduled doses of mRNA-1273 prior to the events, therefore action taken with the drug in response to the events was not applicable.  Concomitant product use was not provided by the reporter.  Treatment information was not provided.
Vaccine administered after more than 1 temperature excursion; Vaccine administered after more than 1 temperature excursion; This spontaneous case was reported by an other health care professional and describes the occurrence of PRODUCT TEMPERATURE EXCURSION ISSUE (Vaccine administered after more than 1 temperature excursion) and POOR QUALITY PRODUCT ADMINISTERED (Vaccine administered after more than 1 temperature excursion) in a 34-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 014M20A) for COVID-19 vaccination.     No Medical History information was reported.    On 27-Feb-2021 at 9:18 AM, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) .5 milliliter. On 27-Feb-2021, the patient experienced PRODUCT TEMPERATURE EXCURSION ISSUE (Vaccine administered after more than 1 temperature excursion) and POOR QUALITY PRODUCT ADMINISTERED (Vaccine administered after more than 1 temperature excursion). At the time of the report, PRODUCT TEMPERATURE EXCURSION ISSUE (Vaccine administered after more than 1 temperature excursion) and POOR QUALITY PRODUCT ADMINISTERED (Vaccine administered after more than 1 temperature excursion) outcome was unknown.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   The age of patient was provided as 34.75.  Concomitant products were not provided.  On 27-FEB-2021, Excursion time was 09 AM,11AM,12PM,1PM,2PM,3PM,4PM and 5PM. temperature was 22,33,35,35,35,35,34,34, and 35 respectively. total doses given for the day was 199, condition of vaccine prior to administration was not frozen, vaccine was moved to fridge on 24-FEB-2021, vial was moved to clinic on 27-FEB-2021. 20 vials were sent to clinic. Vaccine BUD date was 26-MAR-2021.  On 27-FEB-2021, vials were stored in cooler 1, at following time and temperature respectively, 9 AM: 33, 10 AM: 36, 11 AM: 35, 12 AM: 35, 1PM: 35, 2 PM: 35, 3 PM: 34 and 4 PM: 34 and 5PM: 35.  The vials were only punctured right before administration and all doses were drawn from the vial due to high-pace clinic.  Temperature recordings were taken using a Fisher brand traceable temperature monitor at every hour.  After administration, the vial was returned to the freezer/refrigerator, or maintained at room temperature.  It was reported that the patient was administered with vaccines that experienced more than 1 temperature excursion during 33 weeks in 2021. The HCP explained that each time a vial was put into a cooler, there was a period of 1 hour or 1 and half hour approximately, when the temperature data logger registered 34 or 35 degree F.  Treatment medications were not reported.
Vaccine leaked down patient arm; This spontaneous case was reported by a pharmacist and describes the occurrence of INCORRECT DOSE ADMINISTERED (Vaccine leaked down patient arm) in a 40-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 039B21A) for COVID-19 vaccination.     No Medical History information was reported.   On 06-May-2021, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 06-May-2021, the patient experienced INCORRECT DOSE ADMINISTERED (Vaccine leaked down patient arm). At the time of the report, INCORRECT DOSE ADMINISTERED (Vaccine leaked down patient arm) outcome was unknown. Not Provided      For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   No treatment information provided. Concomitants were not reported.  Action taken with mRNA-1273 in response to the events was  not applicable.
Pt presented to the hospital after a cardiac arrest. Work up  showed renal artery thrombosis b/l causing renal failure and hyperkalemia.  ROSC was achieved and pt coded multiple times after.  We were unable to obtain CT A 2/2 to  pt being unstable so only U/S imaging with doppler was used for diagnosis.  Pt was treated with heparin gtt., hematology work up was sent but cause not identified. ECHO did not show thrombosis in the heart. CCRT was attempted but pt expired.